menu

Mechanisms of Acquired Resistance to Targeted Therapies in NSCLC

Be part of the knowledge.
Register

We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?

Register for free

Mechanisms of Acquired Resistance to Targeted Therapies in NSCLC

close
Mechanisms of Acquired Resistance to Targeted Therapies in NSCLC
Restart
Resume
Read full article
Choose a format
Media formats available:
Details
Presenters
Comments
  • Sponsored by

  • Overview

    When a patient with non-small cell lung cancer harboring a molecular driver alteration develops resistance to their therapy, it’s important that we identify what the source of that resistance is, as Dr. Joshua Bauml from the University of Pennsylvania explains.

Facebook Comments

Recommended
Details
Presenters
Comments
  • Sponsored by

  • Overview

    When a patient with non-small cell lung cancer harboring a molecular driver alteration develops resistance to their therapy, it’s important that we identify what the source of that resistance is, as Dr. Joshua Bauml from the University of Pennsylvania explains.

Facebook Comments

LIVE ON REACHMD RADIOBack to live radio

Loading...

Programs 12/3/20